Paul Lee-Archer

Paul Lee-Archer

Auto-generated profile, based on publicly available information

Paul Lee-Archer

Department of Anaesthesia and Pain Management, Queensland Children’s Hospital, Brisbane, Australia; Faculty of Health, Medicine and Behavioural Sciences, University of Queensland, Brisbane, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
SHS Humphreys
S Humphreys
PLP Lee-Archer
P Lee-Archer
GRG Reyne
G Reyne
DLDebbie Long
Debbie Long
TWT Williams
T Williams
ASA Schibler
A Schibler
Transnasal humidified rapid-insufflation ventilatory exchange (THRIVE) was introduced to adult anaesthesia to improve the safety of airway management during apnoea before intubation. The objective of our study was to determine whether THRIVE safely prolongs apnoeic oxygenation in children. This was a randomized controlled trial in 48 healthy children, with normal airways and cardiorespiratory function, in age groups 0-6 and 7-24 months, 2-5 and 6-10 yr old, presenting for elective surgery or imaging under general anaesthesia. All children were induced with sevoflurane, O2, and N2O, followed by muscle relaxation with rocuronium, and standardized preoxygenation with bag-and-mask ventilation. The control arm received jaw support during apnoea, whereas the THRIVE arm received jaw support during apnoea and age-specific flow rates. The primary outcome was to demonstrate that children allocated to THRIVE maintain transcutaneous haemoglobin saturation at least twice as long as the expected age-dependent apnoea time in the control group. Both study arms (each n=24) were similar in age and weight. The apnoea time was significantly shorter in the control arm: average 109.2 (95% CI 28.8) s in the control arm and 192 s in the THRIVE arm (0-6 months), 147.3 (95% CI 18.9) and 237 s (7-24 months), 190.5 (95% CI 15.3) and 320 s (2-5 yr), and 260.8 (95% CI 37.5) and 430 s (6-10 yr), respectively. Average transcutaneous haemoglobin saturation remained at 99.6% (95% CI 0.2) during THRIVE. Transcutaneous CO2 increased to a similar extent in both arms, with 2.4 (95% CI 0.5) mm Hg min-1 for the control arm and 2.4 (95% CI 0.4) mm Hg min-1 for the THRIVE arm. Transnasal humidified rapid-insufflation ventilatory exchange prolongs the safe apnoea time in healthy children but has no effect to improve CO2 clearance. ACTRN12615001319561.

24 August 2020 in Journal of Paediatrics and Child Health
Verified
Journal Article
Open access
PDF file
PLPaul Lee‐Archer
Paul Lee‐Archer
SBSean Blackall
Sean Blackall
HCHolly Campbell
Holly Campbell
DBDaniel Boyd
Daniel Boyd
BPBhavesh Patel
Bhavesh Patel
CMCraig McBride
Craig McBride
Click on the article title to read more.

5 May 2020 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
PLPaul Lee‐Archer
Paul Lee‐Archer
BUBritta Sylvia von Ungern-Sternberg
Britta Sylvia von Ungern-Sternberg

13 June 2020 in Anaesthesia
Verified
Journal Article
Closed access
PDF file
PLP. F. Lee‐Archer
P. F. Lee‐Archer
BUB. S. von Ungern‐Sternberg
B. S. von Ungern‐Sternberg
MRM. Reade
M. Reade
MBM. Betts
M. Betts
DHD. Haenke
D. Haenke
DLDebbie Long
Debbie Long

6 January 2021 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
PLPaul F. Lee‐Archer
Paul F. Lee‐Archer
BUBritta Sylvia von Ungern-Sternberg
Britta Sylvia von Ungern-Sternberg
MRMichael C. Reade
Michael C. Reade
KLK.C. Law
K.C. Law
DLDeborah Long
Deborah Long

16 September 2024 in Anesthesiology
Verified
Journal Article
Open access
RSRita Saynhalath
Rita Saynhalath
NDNicola Disma
Nicola Disma
FTFiona J. Taverner
Fiona J. Taverner
BUBritta Sylvia von Ungern-Sternberg
Britta Sylvia von Ungern-Sternberg
DADean Andropoulos
Dean Andropoulos
OCon behalf of the TREX (Trial Remifentanil DEXmedetomidine) Consortium
on behalf of the TREX (Trial Remifentanil DEXmedetomidine) Consortium
Background: The Trial Remifentanil DEXmedetomidine (TREX) trial aimed to determine whether, in children less than 2 yr old, low-dose sevoflurane/dexmedetomidine/remifentanil anesthesia is superior to standard-dose sevoflurane anesthesia in terms of global cognitive function at 3 yr of age. The aim of the current secondary analyses was to compare incidence of intraoperative hypotension and bradycardia, postoperative pain, time to recovery, need for treatment of intraoperative hypotension and bradycardia, incidence of light anesthesia and need for treatment, need for postoperative pain medications, and morbidity and mortality outcomes at 5 days between the two arms. Methods: This phase III randomized active controlled, parallel group, assessor blinded, multicenter, superiority trial was performed in 20 centers in Australia, Italy, and the United States. A total of 455 infants less than 2 yr of age expected to undergo general anesthesia for at least 2 h were enrolled. They were randomized between low-dose sevoflurane/dexmedetomidine/remifentanil anesthesia and standard-dose sevoflurane. The short-term perioperative outcomes noted above were compared between these two groups. Results: There was less hypotension (risk difference, −11.6%; 95% CI, −18.9 to −4.3%) and more bradycardia (risk difference, 18.2%; 95% CI, 8.8 to 27.7%) in the low-dose sevoflurane/dexmedetomidine/remifentanil anesthesia compared to the standard-dose sevoflurane arm. There were more patients with episodes of light anesthesia (89 vs. 4), and protocol abandonments (1 vs. 0) in the low-dose sevoflurane/dexmedetomidine/remifentanil anesthesia arm. Time from eye opening to postanesthesia care unit discharge was similar in both arms, as were morbidity and mortality. One patient in each arm suffered a life-threatening event, but neither suffered long-term sequelae. Conclusions: These early postoperative results suggest that in children less than 2 yr of age receiving greater than 2 h of general anesthesia, the low-dose sevoflurane/dexmedetomidine/remifentanil anesthesia technique and the standard sevoflurane anesthesia technique are broadly clinically similar, with no clear evidence to support choosing one technique over the other.